UK Clinical Trials Activity Surges 9% as £50M Research Centre and Regulatory Reforms Drive Innovation
核心洞察
Clinical trial applications in the UK increased 9% between January and November 2025, with healthy volunteer studies up 16% and first-in-human trials rising 5%.
The Medical Research Council announced a £50 million Centre of Research Excellence in Clinical Trial Innovation to transform trial design and accelerate patient access to treatments.
New regulatory reforms taking effect in April will introduce fast-track routes for 20% of studies and 14-day assessments for phase 1 trials, aiming to cut setup times from 250 to 150 days.
The UK's clinical trials sector is experiencing a significant resurgence, with new data from the Medicines and Healthcare products Regulatory Agency (MHRA) showing a 9% increase in trial applications between January and November 2025 compared to the same period in 2024. This upturn comes as the country implements sweeping regulatory reforms and launches a groundbreaking £50 million research centre designed to revolutionize clinical trial methodology.
The growth has been particularly pronounced in early-stage research, with healthy volunteer studies increasing by 16% and first-in-human trials rising by 5%. Studies being conducted in the UK for the first time grew by 7%, which the MHRA describes as "a sign of growing international confidence in the UK as a place to launch new research."
Major Investment in Trial Innovation
The Medical Research Council (MRC) Centre of Research Excellence (CoRE) in Clinical Trial Innovation, developed in partnership with the National Institute for Health and Care Research (搜索) (NIHR), will receive up to £50 million over 14 years. Led by Professor Max Parmar, the centre aims to transform the clinical trial landscape by developing new approaches to speed up the process and improve treatment outcomes.
"Basic science is rapidly producing more understanding of biology and consequently many new interventions to help us in a range of diseases," said Professor Parmar. "However, they are too slow and costly meaning it takes some 20 years to get a new invention from the laboratory into routine clinical practice at great expense. Our goal with this CoRE is to substantially reduce this time so that patients can benefit much sooner from new treatments."
The centre plans to move away from testing single interventions in single diseases one at a time, instead developing efficient ways to test multiple drugs in multiple diseases simultaneously. Another focus area involves identifying the minimum intensity required for drug effectiveness, such as finding the lowest effective dose of chemotherapy (搜索) to reduce side effects while maintaining efficacy.
Regulatory Framework Overhaul
Significant regulatory changes will take effect in April, introducing a fast-track notification route that will allow approximately 20% of studies to start more quickly. This streamlined process will focus on lower-risk studies while freeing up regulatory capacity to assess more complex research.
The MHRA will also implement a 14-day assessment route for phase 1 trials, restoring rapid pathways for first-in-human testing of new medicines. Additional reforms include allowing safety data from overseas studies that meet UK standards to be considered and introducing new systems to assess computer simulations, such as in silico trials.
"Clinical trial sponsors are clear about what they need: speed, clarity and flexibility," said MHRA Chief Executive Lawrence Tallon. "New rules will make it simpler to start lower-risk studies, strengthen support for early-stage research and embrace modern approaches, including adaptive trial designs and computer model simulations, while maintaining patient safety."
Industry Engagement and Confidence
The data reveals increased industry engagement with regulators, as companies seek to design trials correctly from the outset. MHRA scientific advice meetings on clinical trials rose by 75% over the reporting period, indicating sponsors' efforts to avoid costly delays later in the development process.
These improvements come after years of decline in the UK's clinical trials sector. A 2022 report from the Association of the British Pharmaceutical Industry (搜索) found a 41% decline in new trial initiations between 2017 and 2021, prompting calls for comprehensive reform.
Government Commitment and Goals
The package of measures supports the UK government's pledge to cut the time from trial application to first participant from around 250 to 150 days. This will be achieved by delivering regulatory decisions within 60 days, opening sites to recruitment within 60 days of approval, and recruiting the first patients within 30 days of trial opening.
Science Minister Lord Vallance emphasized the clinical impact: "By investing £50 million in this new centre, we're helping to speed up the process so patients can access life-changing medicines sooner, with a process that is as rigorous. Bringing forward more effective and targeted treatments will also ease pressure on the NHS, helping to improve care for people across the country."
Collaborative Approach
The MRC CoRE will work with more than 60 organizations worldwide, including researchers, doctors, statisticians, drug companies and regulatory bodies. The leadership group includes researchers from University College London, London School of Hygiene & Tropical Medicine, University of Cambridge, The University of Edinburgh, University of Birmingham, and Newcastle University.
Professor Lucy Chappell, Chief Scientific Adviser at the Department of Health and Social Care and CEO of the NIHR, described the centre as "potentially game-changing for our population," noting it represents "another example of the UK leading on innovation in trial design, speeding up the delivery of clinical trials and accelerating the use of targeted, effective treatments and technologies to patients through research."
Patient Participation Recovery
Patient participation in clinical research has recovered to pre-pandemic levels, with more than 450,000 people participating in studies across England in 2024/25, representing a 17% increase compared to the prior 12-month period. However, participation in commercial trials fell by approximately 25%, highlighting ongoing challenges in the sector.
The reforms align with the government's broader 10 Year Health Plan for England and efforts to modernize the research system. Research published in the British Journal of Clinical Pharmacology shows that 99% of clinical trial applications received by the MHRA are reviewed on time, with most completed well ahead of target.